CUAMC
BCAX

China Universal Asset Management Company’s Bicara Therapeutics BCAX Stock Holding History

China Universal Asset Management Company’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$310K Sell
10,457
-787
-7% -$17.6K 0.02% 315
2026
Q1 		$224K Buy
11,244
+2,317
+26% +$39.9K 0.02% 343
2025
Q4 		$150K Buy
+8,927
New +$152K 0.01% 374

Other funds holding BCAX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
NFT
Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
SAM
SEB Asset Management Stockholm $26.6B AUM

China Universal Asset Management Company's BCAX Position: Q2 2026 in Review

China Universal Asset Management Company reduced its Bicara Therapeutics (BCAX) stake by 7% in Q2 2026, selling an estimated $17.6K and leaving 10,457 shares worth $310K. The position accounts for 0.02% of the portfolio, ranked #315.

China Universal Asset Management Company first reported a position in BCAX in Q4 2025 and has held it in 3 quarters since. 80 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • China Universal Asset Management Company held 10,457 shares of Bicara Therapeutics worth $310K as of Q2 2026.
  • China Universal Asset Management Company sold 787 Bicara Therapeutics shares in Q2 2026, an estimated $17.6K.
  • Bicara Therapeutics made up 0.02% of China Universal Asset Management Company's portfolio in Q2 2026, its #315 holding.
  • China Universal Asset Management Company first reported a position in Bicara Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 80 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on China Universal Asset Management Company's 13F filing for Q2 2026, filed 24 Jul 2026.